Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors.

Neil T ConlonJeffrey J KooijmanSuzanne J C van GerwenWinfried R MulderGuido J R ZamanIrmina DialaLisa D EliAlshad S LalaniJohn CrownDenis M Collins

Published in: British journal of cancer (2021)

Neratinib was the most effective HER2-targeted TKI against HER2-amplified, -mutant, and EGFR-mutant cell lines. This analysis revealed novel resistance mechanisms that may be exploited using combinatorial strategies.

Keyphrases

tyrosine kinase
cancer therapy
single cell
small cell lung cancer
wild type
epidermal growth factor receptor
chronic myeloid leukemia
advanced non small cell lung cancer
gene expression
genome wide
positive breast cancer
genome wide identification
dna methylation
adverse drug
genome wide analysis
data analysis